Why athletes with cartilage defects often end up at this choice

Sitting across from a consultant after an MRI, a 26-year-old footballer hears that they have a full-thickness cartilage lesion on the medial femoral condyle. The cartilage is gone to bone over a coin-sized area, graded ICRS III or IV, and the knee is telling them about it every time they cut or land. The immediate clinical question is not anatomical — it is whether the right repair will still be holding up in ten years, when the athlete still wants to be playing.

For lesions broadly in the 1–2 cm² range, two procedures dominate the conversation: microfracture and osteochondral autograft transfer (OATS, also performed as mosaicplasty). They were developed in different eras and work through entirely different biology, yet they compete directly in this defect-size window and in this patient profile — young, physically active, biomechanically demanding.

Microfracture was historically the first-line answer for smaller defects: quick, arthroscopic, no donor site. OATS emerged as an alternative that transplants genuine bone-and-cartilage plugs rather than stimulating a healing response from the marrow. The distinction matters because long-term follow-up data — now extending to a decade — have made it possible to ask which tissue actually survives athletic loading over time.

Published meta-analyses report an overall return-to-sport rate of 76–78% across all knee cartilage restoration techniques. That headline figure spans microfracture, OATS, ACI, and allograft. The question an athlete reasonably asks is whether the choice between microfracture and OATS moves that number — and whether any early gains are still present at five or ten years.

How OATS works and what it transplants

The procedure harvests one or more cylindrical plugs — each comprising a column of subchondral bone capped with its native hyaline cartilage surface — from a relatively low-load region of the same knee, typically the peripheral trochlea or intercondylar notch margin. These plugs are press-fit into pre-drilled recipient tunnels at the defect site so that the transplanted cartilage surface sits flush with the surrounding joint surface.

When mosaicplasty is used, several smaller plugs (usually 6–8 mm in diameter) are arranged in a mosaic pattern across the defect, allowing coverage of areas up to approximately 4 cm². A single-plug OATS approach is generally suited to defects in the 1–2 cm² range. The procedure is single-stage and performed arthroscopically or through a small mini-open incision, which distinguishes it practically from two-stage techniques such as MACI or ACI, where a biopsy and a separate implantation operation are required.

What the graft delivers is structurally meaningful: native type II hyaline cartilage on an intact subchondral bone base, biochemically and mechanically matched to the surrounding joint surface. The spaces between plugs in a mosaicplasty arrangement, however, fill with fibrocartilage ingrowth rather than hyaline tissue — reducing the net hyaline coverage of the repair zone. Donor-site harvest also carries the risk of localised pain or defect at the collection site, and the autograft supply is finite, setting a practical ceiling on defect size that can be addressed with this technique.

The biological argument: hyaline cartilage versus fibrocartilage at ten years

The distinction between tissue types is not an academic footnote — it is the reason outcomes diverge over time.

Microfracture works by perforating the subchondral bone plate with small awls, allowing marrow blood and stem cells to flood the defect. The clot that forms matures into repair tissue, but that tissue is predominantly type I fibrocartilage rather than native articular cartilage. Functionally, fibrocartilage behaves more like scar tissue than joint surface: it is less stiff, less resilient under repetitive compressive load, and over years it tends to break down — often accompanied by subchondral sclerosis and cystic change beneath the repair site. In a knee absorbing hundreds of high-impact cycles per training session, this mechanical inferiority compounds gradually.

OATS sidesteps that problem entirely. The transplanted plug carries intact type II hyaline cartilage — the native tissue of the joint surface — on its original calcified cartilage and subchondral bone base. The zonal architecture (superficial, transitional, radial, and calcified layers) arrives intact rather than having to reform from a marrow clot. Two 2024 papers converge in identifying this biological difference as the mechanistic explanation for OATS's superior durability at longer follow-up. The mechanism is well-understood even if a head-to-head trial has not tested it directly at ten years.

A practical corollary concerns what happens if microfracture fails. Drilling the subchondral plate can disrupt the bone architecture beneath the defect, and that disruption may complicate — or in some cases compromise — any subsequent cartilage restoration procedure. For an athlete who may still be in their late twenties at the point of failure, that sequencing risk is a clinically meaningful consideration.

Ten-year OATS outcome data: what the numbers actually show

The clearest decade-level evidence comes from a 2024 institutional registry study of 63 patients with a mean age of 27.4 years and a mean lesion size of 2.3 cm². Mean IKDC scores rose from 46.4 before surgery to 70.4 at ten years, and KOS-ADL scores from 64.4 to 83.8. In practical terms, that trajectory spans the gap between limiting sport participation and managing stairs, to loading the knee well enough to train, run, and take the field — a shift most patients would consider the reason they had surgery in the first place.

The MCID data add an important qualification. At two years, 69% of patients exceeded the minimum clinically important difference threshold for IKDC; by ten years, that proportion had fallen to 60%. This is honest signal, not failure: a meaningful majority retained clinically worthwhile benefit at a decade, but the curve does not plateau — it gradually attenuates. Patients should be counselled on this trajectory rather than anchored to early results.

Joint preservation held well. Only 2 of 63 patients (3.2%) required conversion to arthroplasty at ten years — the core outcome in any young-knee preservation discussion. The overall reoperation rate of 28.6% sounds more alarming than it is: the predominant interventions were partial meniscectomy, chondroplasty, and loose body removal, not revision of the osteochondral construct itself. Distinguishing secondary procedures from construct failure matters in counselling.

The Gudas series, published from Lithuania across 2005–2013 and consistently favouring mosaicplasty over microfracture at follow-up, pointed in the same direction. The 2024 registry data broadly confirm that signal at a longer time horizon, with the MCID attenuation now quantified where Gudas could not.

Microfracture's attrition pattern and what head-to-head trials show

Stark as the OATS durability figures are, microfracture's own long-term trajectory in athletes makes the comparison starker still. A 2025 cohort study of 50 elite athletes — 60% footballers — reported a 94% return-to-play rate at a mean of 9.3 months after microfracture. That early figure is routinely cited as a success; what follows it is not. By two years, 86% of those same athletes were still playing; by five years, only 54.5% remained active. The mechanism of this attrition aligns precisely with the fibrocartilage deterioration described earlier — the repair tissue breaks down under repeated load, and athletes progressively drop out of sport rather than returning for formal revision.

Lesion size drives that trajectory. Defects exceeding 2 cm in diameter significantly reduced both initial return-to-play (p = 0.048) and five-year continuation (p = 0.002). This threshold matters because those larger lesions represent exactly the patients most likely to be considered for OATS in the first place.

Direct head-to-head trial data is more limited than the clinical consensus might suggest. The best-powered prospective randomised study enrolled 56 athletes across football, volleyball, and combat sports, comparing 42 microfracture cases against 14 treated with mosaicplasty over a mean follow-up of 2.3 years. Mosaicplasty outperformed microfracture by 1.5 Lysholm points and 2.7 KOOS points — but the result did not reach statistical significance. With only 14 patients in the mosaicplasty arm and follow-up of under three years, the study was underpowered to detect modest but clinically real differences, particularly those that emerge later in the degenerative curve. A 2021 JAAOS review and 2024 commentary both conclude that OAT yields the highest return-to-sport rate and highest rate of return to pre-injury level across all cartilage restoration techniques in high-level athletes — though both acknowledge that lesion-size heterogeneity between cohorts limits certainty.

No single ten-year randomised controlled trial comparing OATS directly with microfracture exclusively in athletes currently exists. The clinical picture rests on registry cohorts, systematic reviews, and the Gudas series rather than on one definitive study. The direction of evidence is consistent; the ceiling is methodological.

Who is a realistic OATS candidate and what assessment involves

Eligibility, in practice, is more selective than the outcome data alone might suggest. Published cohorts favour patients typically under 50, with focal contained defects of 1 to 4 cm², no significant osteoarthritic change (Kellgren-Lawrence grade ≤2), and BMI within normal limits. These thresholds define the population whose decade-level results are actually documented. When an athlete falls outside them, assessment redirects towards alternative reconstruction rather than an adapted attempt at OAT.

Donor-site availability sets a structural ceiling at roughly 4 cm² for mosaicplasty. Beyond that size, fresh osteochondral allograft (OCA) or cell-based repair such as MACI becomes more appropriate. Alignment problems — varus or valgus deformity loading the repaired compartment — may also need surgical correction alongside the cartilage procedure; unaddressed mechanics undermine the biology regardless of tissue quality.

For the appropriately selected athlete, the decade-level data provide a more specific frame than the broad return-to-sport benchmarks cited earlier. Where microfracture leaves only 54.5% of elite athletes still competing at five years, OATS maintains 60% of patients above the minimum clinically important improvement threshold at ten — a different trajectory, not a guarantee. Choosing OATS means accepting a more demanding procedure and a longer rehabilitation in exchange for repair tissue that the evidence suggests holds up better under sustained athletic load. That trade-off is well founded when the patient fits the criteria; when they do not, the right answer usually lies elsewhere.

Assessment covering lesion size and grade, subchondral bone quality, limb alignment, and the demands of the athlete's sport determines which approach — or which combination — is appropriate. Athletes considering cartilage restoration can request a specialist assessment at londoncartilage.com.

1. [1] Comparative analysis of long-term results of treatment of patients with osteochondral knee injuries (prospective, randomized study). (2019). https://doi.org/10.17238/issn2223-2524.2019.2.79 https://doi.org/10.17238/issn2223-2524.2019.2.79
2. [2] Arthroscopic versus Open Osteochondral Autograft Transplantation (Mosaicplasty) for Cartilage Damage of the Knee: A Systematic Review. (2019). https://doi.org/10.1055/s-0039-1692999 https://doi.org/10.1055/s-0039-1692999
3. [3] Functional Outcomes and Return to Sport After Cartilage Restoration of the Knee in High-level Athletes.. (2021). https://doi.org/10.5435/JAAOS-D-21-00242 https://doi.org/10.5435/JAAOS-D-21-00242
4. [4] Long-Term Outcomes of Autologous Osteochondral Transfer of the Knee Are Successful and Predicated Upon Appropriate Patient Selection.. (2024). https://doi.org/10.1016/j.arthro.2024.03.012 https://doi.org/10.1016/j.arthro.2024.03.012
5. [5] Microfracture for full-thickness chondral lesions of the knee in elite athletes leads to high return-to-play rates. (2025). https://doi.org/10.1002/ksa.12808 https://doi.org/10.1002/ksa.12808
6. [6] Mosaicplasty/Osteochondral Autograft Transfer Remains a Durable Solution for Symptomatic Chondral Defects of the Knee: Two to Ten-Year Follow-up Analysis. (2024). https://doi.org/10.1177/2325967124s00003 https://doi.org/10.1177/2325967124s00003